CN119345359A - 用于膀胱癌的新辅助疗法 - Google Patents

用于膀胱癌的新辅助疗法 Download PDF

Info

Publication number
CN119345359A
CN119345359A CN202411498667.9A CN202411498667A CN119345359A CN 119345359 A CN119345359 A CN 119345359A CN 202411498667 A CN202411498667 A CN 202411498667A CN 119345359 A CN119345359 A CN 119345359A
Authority
CN
China
Prior art keywords
composition
bladder
use according
bladder cancer
hal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202411498667.9A
Other languages
English (en)
Chinese (zh)
Inventor
K·赫斯特达尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Photocure ASA
Original Assignee
Photocure ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Photocure ASA filed Critical Photocure ASA
Publication of CN119345359A publication Critical patent/CN119345359A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0061—5-aminolevulinic acid-based PDT: 5-ALA-PDT involving porphyrins or precursors of protoporphyrins generated in vivo from 5-ALA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0613—Apparatus adapted for a specific treatment
    • A61N5/062—Photodynamic therapy, i.e. excitation of an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N5/0601—Apparatus for use inside the body
    • A61N5/0603—Apparatus for use inside the body for treatment of body cavities
    • A61N2005/061—Bladder and/or urethra
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0626—Monitoring, verifying, controlling systems and methods
    • A61N2005/0629—Sequential activation of light sources
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/06—Radiation therapy using light
    • A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
    • A61N2005/0662—Visible light
    • A61N2005/0663—Coloured light
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202411498667.9A 2015-12-17 2016-12-19 用于膀胱癌的新辅助疗法 Pending CN119345359A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB1522309.2 2015-12-17
GBGB1522309.2A GB201522309D0 (en) 2015-12-17 2015-12-17 Use
PCT/EP2016/081803 WO2017103283A1 (en) 2015-12-17 2016-12-19 Neoadjuvant therapy for bladder cancer
CN201680079674.2A CN108601836A (zh) 2015-12-17 2016-12-19 用于膀胱癌的新辅助疗法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680079674.2A Division CN108601836A (zh) 2015-12-17 2016-12-19 用于膀胱癌的新辅助疗法

Publications (1)

Publication Number Publication Date
CN119345359A true CN119345359A (zh) 2025-01-24

Family

ID=55311159

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202411498667.9A Pending CN119345359A (zh) 2015-12-17 2016-12-19 用于膀胱癌的新辅助疗法
CN201680079674.2A Pending CN108601836A (zh) 2015-12-17 2016-12-19 用于膀胱癌的新辅助疗法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680079674.2A Pending CN108601836A (zh) 2015-12-17 2016-12-19 用于膀胱癌的新辅助疗法

Country Status (14)

Country Link
US (2) US10556010B2 (enExample)
EP (1) EP3389717B9 (enExample)
JP (1) JP6926086B2 (enExample)
KR (1) KR102787188B1 (enExample)
CN (2) CN119345359A (enExample)
AU (1) AU2016372573B2 (enExample)
BR (1) BR112018012009B1 (enExample)
CA (1) CA3008551A1 (enExample)
DK (1) DK3389717T3 (enExample)
ES (1) ES3015668T3 (enExample)
FI (1) FI3389717T3 (enExample)
GB (1) GB201522309D0 (enExample)
PL (1) PL3389717T3 (enExample)
WO (1) WO2017103283A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
GB201522311D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
PH12020550124B1 (en) * 2017-12-01 2024-05-24 Nat Ct Child Health & Dev Pharmaceutical composition for enhancing antitumor effect by immune checkpoint inhibitor
KR102441358B1 (ko) 2020-09-14 2022-09-06 주식회사 아파트엔 아파트의 지수화를 통한 아파트 투자 가치 평가 시스템
AU2024231397A1 (en) 2023-03-07 2025-09-25 Photocure Asa Therapy for bladder cancer

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ291132B6 (cs) 1995-03-10 2002-12-11 Photocure Asa Estery kyselin 5-aminolevulových a farmaceutický prostředek s jejich obsahem
US7530461B2 (en) * 1995-03-10 2009-05-12 Photocure Asa Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
GB0018528D0 (en) * 2000-07-27 2000-09-13 Photocure Asa Compounds
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
GB0406917D0 (en) 2004-03-26 2004-04-28 Photocure Asa Compounds
CN109485727A (zh) 2005-05-09 2019-03-19 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
KR101411165B1 (ko) 2005-07-01 2014-06-25 메다렉스, 엘.엘.시. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체
NZ600758A (en) 2007-06-18 2013-09-27 Merck Sharp & Dohme Antibodies to human programmed death receptor pd-1
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
CN102458388B (zh) 2009-06-11 2016-09-28 光治疗Asa公司 半固体组合物及药物制品
AR087405A1 (es) 2011-08-01 2014-03-19 Genentech Inc Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1 e inhibidores de mek
EP2785375B1 (en) 2011-11-28 2020-07-22 Merck Patent GmbH Anti-pd-l1 antibodies and uses thereof
EP2855528B1 (en) 2012-05-31 2019-06-19 Genentech, Inc. Methods of treating cancer using pd-l1 axis binding antagonists and vegf antagonists
US8927761B2 (en) 2012-06-28 2015-01-06 Photocure Asa Form of hexyl-5-aminolevulinate hydrochloride and methods of using the same
WO2014020164A1 (en) * 2012-08-03 2014-02-06 Photocure Asa Compounds
GB201522309D0 (en) * 2015-12-17 2016-02-03 Photocure Asa Use
CN109010850B (zh) * 2018-08-01 2021-10-22 上海师范大学 一种负载姜黄素的葡聚糖修饰的钆掺杂的空心介孔二氧化硅纳米材料的制备方法及应用

Also Published As

Publication number Publication date
GB201522309D0 (en) 2016-02-03
EP3389717A1 (en) 2018-10-24
JP2018537514A (ja) 2018-12-20
AU2016372573B2 (en) 2022-07-21
DK3389717T3 (da) 2025-03-31
US20200155683A1 (en) 2020-05-21
US11311620B2 (en) 2022-04-26
JP6926086B2 (ja) 2021-08-25
KR102787188B1 (ko) 2025-03-25
PL3389717T3 (pl) 2025-06-09
CN108601836A (zh) 2018-09-28
US20180369379A1 (en) 2018-12-27
BR112018012009B1 (pt) 2023-12-19
AU2016372573A1 (en) 2018-07-12
BR112018012009A2 (pt) 2018-12-04
RU2018124868A3 (enExample) 2020-05-13
FI3389717T3 (fi) 2025-04-08
EP3389717B9 (en) 2025-07-23
ES3015668T3 (en) 2025-05-07
WO2017103283A1 (en) 2017-06-22
EP3389717B1 (en) 2025-02-19
US10556010B2 (en) 2020-02-11
KR20180094987A (ko) 2018-08-24
RU2018124868A (ru) 2020-01-27
CA3008551A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
US11311620B2 (en) Neoadjuvant therapy for bladder cancer
US11066478B2 (en) Intravesical therapy for bladder cancer
CA3008552C (en) Method of photodynamic therapy (pdt) for bladder cancer
RU2783177C2 (ru) Неоадъювантная терапия для рака мочевого пузыря
RU2779543C2 (ru) Внутрипузырная терапия для рака мочевого пузыря
AU2024231397A1 (en) Therapy for bladder cancer
HK1262650A1 (en) Method of photodynamic therapy (pdt) for bladder cancer
HK1262650B (en) Method of photodynamic therapy (pdt) for bladder cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination